AtriCure (NASDAQ:ATRC) Insider Salvatore Privitera Sells 4,519 Shares of Company Stock

AtriCure, Inc. (NASDAQ:ATRC) insider Salvatore Privitera sold 4,519 shares of the business’s stock in a transaction that occurred on Wednesday, September 23rd. The shares were sold at an average price of $60.00, for a total value of $271,140.00. Following the completion of the transaction, the insider directly owned 142,745 shares of the company’s stock, valued at $8,564,700. The trade was a 3.07% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Salvatore Privitera also recently made the following trade(s):

• On Tuesday, September 8th, Salvatore Privitera sold 3,657 shares of AtriCure stock. The stock was sold at an average price of $55.00, for a total value of $201,135.00.
• On Wednesday, September 2nd, Salvatore Privitera sold 7,763 shares of AtriCure stock. The stock was sold at an average price of $52.50, for a total transaction of $407,557.50.

AtriCure Price Performance

NASDAQ:ATRC opened at $60.77 on Friday. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.22 and a quick ratio of 3.19. The firm has a market cap of $3.09 billion, a price-to-earnings ratio of 289.39 and a beta of 1.26. The company has a 50 day moving average price of $46.76 and a 200-day moving average price of $35.29. AtriCure, Inc. has a 1-year low of $25.36 and a 1-year high of $61.70.

AtriCure (NASDAQ:ATRC) last posted its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share (EPS) for the quarter. The firm had revenue of $153.60 million during the quarter, compared to analysts’ expectations of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same period in the previous year, the business posted ($0.13) EPS. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. Equities research analysts forecast that AtriCure, Inc. will post 0.29 EPS for the current year.

Institutional Investors Weigh In On AtriCure

Large investors have recently bought and sold shares of the stock. BlackRock Inc. acquired a new stake in shares of AtriCure in the 2nd quarter valued at $125,198,000. Bank of America Corp DE purchased a new stake in AtriCure during the 2nd quarter worth about $24,465,000. Grandeur Peak Global Advisors LLC purchased a new stake in AtriCure during the 2nd quarter worth about $16,435,000. Osterweis Capital Management Inc. acquired a new position in shares of AtriCure during the 2nd quarter worth about $14,028,000. Finally, Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of AtriCure during the 2nd quarter worth about $9,388,000. Hedge funds and other institutional investors own 99.11% of the company’s stock.

Analyst Upgrades and Downgrades

ATRC has been the subject of several recent analyst reports. Piper Sandler lifted their price target on AtriCure from $50.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, August 27th. Zacks Research cut AtriCure from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 24th. Weiss Ratings raised AtriCure from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, August 19th. Needham & Company LLC boosted their price target on shares of AtriCure from $45.00 to $64.00 and gave the stock a “buy” rating in a report on Wednesday, September 2nd. Finally, BTIG Research upped their price objective on shares of AtriCure from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Monday, August 24th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $53.30.

About AtriCure

AtriCure, Inc (NASDAQ: ATRC) is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.